<?xml version="1.0" encoding="UTF-8"?>
<p>Exposure to high doses of PG may affect the Central Nervous System, especially in new-borns and children under 4 years of age [
 <xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. Due to childrenâ€™s physiological and metabolic immaturity, PG can accumulate rapidly causing toxicity [
 <xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>]. In new-borns, its half-life is very long, almost seventeen hours, compared to that of adults, which is about five hours [
 <xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]. The GRAS (Generally Recognized as Safe) classification of excipients typically does not consider the differences in physiological and metabolic maturation between the paediatric and adult populations [
 <xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>], a fact that justifies some important adverse reactions presented by PG in the paediatric population [
 <xref rid="B29-pharmaceutics-13-00387" ref-type="bibr">29</xref>]:
 <list list-type="bullet">
  <list-item>
   <p>Hyperosmolar syndrome in burnt children with topical arsenic sulfadiazine ointment containing PG.</p>
  </list-item>
  <list-item>
   <p>Precipitation of irreversible deafness in pretermits who received a multivitamin complex containing PG.</p>
  </list-item>
  <list-item>
   <p>Parenterally it is possible to observe haemolysis, seizures, respiratory depression, hypertension.</p>
  </list-item>
  <list-item>
   <p>Contact dermatitis is topically observed.</p>
  </list-item>
 </list>
</p>
